louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06507397: Dural Puncture Epidural Anesthesia Versus Traditional Spinal Anesthesia for Rigid Cystoscopy
Official title: Dural Puncture Epidural Anesthesia Versus Traditional Spinal Anesthesia for Rigid Cystoscopy: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dural Puncture Epidural Anesthesia
Spinal Anesthesia
Rigid Cystoscopy
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2024-07-18
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The main objective of this study was to determine if the dural puncture epidural (DPE) anesthesia provides superior analgesia and better patient satisfaction when compared to traditional spinal anesthesia for rigid cystoscopy.

Detailed description: Most urologic surgeries are performed in a narrow and limited space with the minimally invasive technique or cystoscope, and most patients undergoing urologic surgeries are elderly individuals with other diseases.

Cystoscopic evaluation of the lower urinary tract is a vital part of an office-based urologic practice. However, regular surveillance cystoscopy is a significant source of morbidity for patients, and therefore attempts have been made to minimize discomfort secondary to this procedure.

Spinal anesthesia is popular for endoscopic urological surgery because of early recognition of symptoms caused by overhydration, transurethral resection of prostate (TURP) syndrome and bladder perforation.

The dural puncture epidural (DPE) technique is a modification of the combined spinal epidural (CSE) technique, where a dural perforation is created from a spinal needle but intrathecal medication administration is withheld. The DPE technique has been shown to improve caudal spread of analgesia compared with epidural (EPL) technique without the side effects observed with the CSE technique.

Eligibility criteria: Inclusion Criteria:

* Age ≥18 years.
* Both sex.
* American Society of Anesthesiology (ASA) physical status I, II, III.
* Admitted for elective rigid cystoscopy.

Exclusion Criteria:

* Refusal of patients.
* Body Mass Index (BMI) \> 35.
* Patients who have history of substance abuse.
* Patients with difficult communication.
* Contraindication to neuraxial anesthesia (e.g.; infection near the site of injection, coagulopathy or bleeding disorder).
* Patients with history of allergy to local anesthetics.

Primary outcomes:
measure: Assessment of the onset of anesthesia
timeFrame: Every 15 minutes till end of the surgery
Secondary outcomes:
measure: Time of onset of motor block
timeFrame: Till the end of the surgery
measure: Incidence of side effects
timeFrame: 24 hours postoperatively
measure: Number of patients required rescue analgesia
timeFrame: 24 hours postoperatively
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: El-Gharbia
Study officials:
References:
Clinical trial NCT05867797: Risk Factors and Outcomes of Acute Kidney Injury in Patients With Diabetic Ketoacidosis at Sohag University Hospital.
Official title: Risk Factors and Outcomes of Acute Kidney Injury in Patients With Diabetic Ketoacidosis at Sohag University Hospital.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diabetic Ketoacidosis
Acute Kidney Injury
Keywords: DKA AKI
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-05-22
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diabetic ketoacidosis at Sohag university hospital for all patients admitted during the period from May 2023 to May 2024

Brief summary: Diabetic ketoacidosis (DKA), a severe complication of diabetes mellitus (DM), is the leading cause of hospitalization, morbidity and mortality in patients with DM (1).

DKA is associated with hyperglycemic crises and featured by metabolic acidosis, the production of ketoacids, volume depletion, and electrolyte imbalance. Due to glucose-induced osmotic polyuria and even emesis, volume depletion is a major cause of acute kidney injury (AKI) in DKA patients (2).


Eligibility criteria: Inclusion Criteria:

* patients will be included in this study aged \>18 years old after diagnosis of AKI on top of Diabetic ketoacidosis at Sohag university hospital for all patients admitted during the period from May 2023 to May 2024

Exclusion Criteria:

* Chronic kidney disease

Primary outcomes:
measure: prognosis risk factors and outcomes of AKI in patients with DKA
timeFrame: 1 YEAR
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00752583: Peritoneal Dialysis Versus Haemodialysis
Official title: Clinical Study in Order to Quantify Solute Removal in Peritoneal Dialysis Versus Haemodialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemodialysis
Keywords: Chronic renal insufficiency (patients under dialysis)
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2008-09-15
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Study in order to quantify toxin removal during dialysis


Eligibility criteria: Inclusion Criteria:

* Substudy 1: includes new starting dialysis patients on peritoneal dialysis PD or haemodialysis HD
* Substudy 2: stabile haemodialysis patients and peritoneal dialysis patients. Patients will be matched for gender, time on dialysis, diabetes, renal function at the start of dialysis.
* Substudy 3: patients on CAPD (continuous ambulant PD) or CCPD (continuous cyclic PD).

Primary outcomes:
measure: Registration of toxin removal efficiency
timeFrame: After 1 week and after 1, 3, 6, 9, 12, 18 and 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Raymond Vanholder, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01982383: Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy
Official title: A Prospective Study of the Use of Micropulse 577nm Laser Treatment in Central Serous Chorioretinopathy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Central Serous Chorioretinopathy
Keywords: CSC
Edema
Retinopathy
Lead sponsor: George Washington University
Sponsor class: OTHER
First posted: 2013-11-13
Enrollment: 2
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators hypothesis is that using the micropulse laser in patient with Central Serous Chorioretinopathy (CSC) will prompt resolution of CSC and will be effective in significantly minimizing visual recovery time from this disease as well as potentially preventing recurrences.

Detailed description: The investigators hypothesize that application of 577nm micropulse laser in patients with CSC will prompt resolution of CSC as measured by ocular coherence tomography and best corrected visual acuity. This will be a pilot study to establish sound methods and provide some insights to the safety and efficacy of CSC treatment.

Eligibility criteria: Inclusion Criteria:

* Patients with new diagnosis of CSC and no other comorbidities or prior retinal treatment
* Patients ranging from 30 to 60 years of age

Exclusion Criteria:

* Patients with no case of CSC
* Patients with other macular comorbidities including but not limited to diabetic retinopathy, macular degeneration
* Patients with prior retinal treatment

Primary outcomes:
measure: Resolution of Fluid Build-up
timeFrame: within 1 week to 3 months after the laser procedure is completed
Secondary outcomes:
Other outcomes:
Locations:
city: Washington
country: United States
facility: George Washington University Medical Faculty Associates
state: District of Columbia
Study officials:
affiliation: George Washington University
name: Jeevan Mathura, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ricci F, Missiroli F, Cerulli L. Indocyanine green dye-enhanced micropulsed diode laser: a novel approach to subthreshold RPE treatment in a case of central serous chorioretinopathy. Eur J Ophthalmol. 2004 Jan-Feb;14(1):74-82. doi: 10.1177/112067210401400115.
citation: Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008 Nov-Dec;18(6):934-40. doi: 10.1177/112067210801800613.
citation: Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008 Dec;115(12):2229-34. doi: 10.1016/j.ophtha.2008.08.026.
Clinical trial NCT02025283: Efficacy of Radiofrequency Nucleoplasty and Targeted Disc Decompression in Lumbar Radiculopathy
Official title: The Comparison of the Efficacy of Radiofrequency Nucleoplasty and Targeted Disc Decompression in Lumbar Radiculopathy: A Retrospective Review
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Visual Analogue Pain Scale
Pain Measurement
Keywords: Intervertebral disc disease
Radiculopathy
Chronic pain
Thermocoagulation
Lead sponsor: Ankara University
Sponsor class: OTHER
First posted: 2014-01-01
Enrollment: 73
Sex: ALL
Minimum age (years): 35
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 120 patients with lumbar radiculopathy undergoing nucleoplasty and targetted disc decompression in Algology Department of a University Hospital between 2010 and 2012 were retrospectively evaluated and complete data of only 73 patients were reached and they were included to the study

Brief summary: The aim of this study is to compare early and long term efficacy of lumbar radiofrequency nucleoplasty and targeted disc decompression in patients with lumbar radiculopathy who failed previous conventional therapy. Medical records of 37 patients undergoing targeted disc decompression, 36 patients undergoing lumbar radiofrequency nucleoplasty were retrospectively examined.Visual Analogue Scale (VAS), Numerical Rating Scale (NRS), Functional Rating Index, Backache index, Oswestry Lumbar Back Pain Disability Index, Rolland-Morris Lumbar Back Pain Questionnaire scales were used before treatment and 1,6,12 months after the procedure. North American Spine Society Satisfaction Scale was used at 12th month after the procedure.


Eligibility criteria: Inclusion Criteria:

* patients having radicular pain with or without low back pain for at least 6 weeks inspite of conservative treatment who have unsequestrated, bulging, protruded or extruded hernia confirmed with MRI.

Exclusion Criteria:

* patients having a more than 50% loss in disc area, sequestrated disc, the presence of vertebra fracture or tumor, the patients having spinal stenosis or spondylolisthesis

Primary outcomes:
measure: Decrease in Visual Analogue Scale (VAS)
timeFrame: 12 months
Secondary outcomes:
measure: More than 50% procedure-related patient satisfaction ratio in North American Spine Society Satisfaction Scale
timeFrame: 12 months
Other outcomes:
measure: Decrease in Numerical Rating Scale
timeFrame: 12 months
measure: Decrease in Functional Rating Index
timeFrame: 12 months
Locations:
city: Ankara
country: Turkey
facility: Ankara University Medical School Algology Department
Study officials:
affiliation: Ankara University
name: Barış Adaklı, Specialist
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00703183: Safety and Tolerability of ACU-4429
Official title: A Single Center, Randomized, Double-Masked, Dose-Escalating, Placebo-Controlled Study of the Safety and Tolerability ACU-4429 in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Kubota Vision Inc.
Sponsor class: INDUSTRY
First posted: 2008-06-23
Enrollment: 46
Sex: ALL
Minimum age (years): 55
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and tolerability of a new investigational drug (ACU-4429) in healthy human volunteers.


Eligibility criteria: Inclusion Criteria:

* Is male or female with age ≥ 55 and ≤ 80 years at the time of consent
* Is healthy as determined by medical history and physical examination

Exclusion Criteria:

* Is receiving or has recently received treatment with a medication disallowed per the protocol

Primary outcomes:
measure: Safety and tolerability
timeFrame: 7 days
Secondary outcomes:
measure: Pharmacokinetics
timeFrame: 2 days
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Covance Clinical Research Unit, Inc
state: Texas
Study officials:
affiliation: Covance
name: William W Lewis, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02391883: Hip-Fracture Surgery on Patients in Clopidogrel Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hip Fracture
Keywords: clopidogrel therapy
platelet aggregation inhibitor
adverse event
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
First posted: 2015-03-18
Enrollment: 356
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 356 patients were included in the final analysis. Out of this group we identified 36 patients taking Clopidogrel. 24 of these were in DAPT. 12 patients were in Clopidogrel therapy alone. The indications for treatment were: CNS thrombosis (n=14); Unstable Angina (n=8); Peripheral Atherosclerosis (n=3); Myocardial Infarction (n=2); Insertion of stent \>24 months earlier (n=1); and Unknown indication (n=8). All patients had their treatment discontinued on admission.

All analyzed patients were operated within 24 hours of admission (n=356).

Brief summary: Patients in Clopidogrel therapy alone or in combination with acetylsalicylic acid (Dual Antiplatelet Therapy (DAPT) presenting with a hip-fracture represent the surgeon with the dilemma of putting the patient at risk of a major blood loss during and after surgery, or putting the patient at risk of a thromboembolic event after surgery. The investigators hypothesize that the risk of a major blood loss in patients that are still under the effect of Clopidogrel or DAPT during or after hip-fracture surgery is relatively low. The investigators have conducted a retrospective observational study on hip-fracture patients to test this hypothesis.


Eligibility criteria: Inclusion Criteria:

* All patients operated with short intramedullary nail for hip-fractures, in the study period. (1st of Jan. 2011-31st of Dec. 2013)

Exclusion Criteria:

* patients operated \>24 hours after admission, patients in other forms of anticoagulation medication except acetylsalicylic acid (including vitamin K antagonists, dipyridamole, dabigatran, apixaban and rivaroxaban), missing data on blood loss in patient chart, missing blood samples in the first 4 days and extra-national patients (follow up not possible). Patients operated on both sides during the inclusion period were only included with data on their latest operation.

Primary outcomes:
measure: Surgical Blood Loss
timeFrame: at time of surgery
Secondary outcomes:
measure: Total BLood Loss
timeFrame: From admission to third day after surgery.
measure: Number of transfusions
timeFrame: From admission to third day after surgery
measure: 30 and 90 day mortality
timeFrame: 30 and 90 days postoperatively
measure: Massive transfusion
timeFrame: within 24 hours of surgery
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06389383: Pilot Study - Monitoring the Nasal Microbiome and Viral Respiratory Infections in Newborn Hospitalized in Neonatalogy.
Official title: Pilot Study - Monitoring the Nasal Microbiome and Viral Respiratory Infections in Newborn Hospitalized in Neonatalogy. Metatranscriptomic Approach by New Generation Sequencing From High Respiratory Swabs.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Newborn; Infection
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
First posted: 2024-04-29
Enrollment: 38
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The objective of our study is therefore to study the evolution of the respiratory microbiome of hospitalized newborns, its interaction with viral infections and their impacts on the evolution of newborns.


Eligibility criteria: Inclusion Criteria:

* Newborn hospitalized in intensive care or neonatal intensive care.
* Whose parents were able to be informed of the study and who signed consent.
* Parents affiliate to the social security system

Exclusion Criteria:

* Refusal of parental consent
* Parents who are minors or under guardianship, curatorship, safeguard of justice or legal protection.
* Newborn having already left the hospital/returned home before inclusion
* Hospitalization beyond the first 48 hours of life
* Only palliative care.

Primary outcomes:
measure: rate of viral infections
timeFrame: from baseline to end of hospitalization (up to 2 months)
Secondary outcomes:
Other outcomes:
Locations:
city: Caen
country: France
facility: CAEN University Hospital
Study officials:
References:
Clinical trial NCT03789383: Risk Factors and Outcome of Biliary Complications Following Adult Living Donor Liver Transplantation
Official title: Risk Factors and Outcome of Biliary Complications Following Adult Living Donor Liver Transplantation in Al-Rajhy Liver Hospital in Upper Egypt.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Liver Transplant; Complications
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2018-12-28
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults more than 18 y with living donor liver transplantation in Al-Rajhy liver hospital, Assiut university, Egypt.

Brief summary: Liver transplantation (LT) is a live-saving therapy for patients with complicated chronic liver diseases and acute liver failure .Even though many complications can occur after LT, biliary complications (BC) are both common and potentially severe .

a prospective study and retrospective part from hospital records.

Aim of the study:

1. Detect frequency, risk factors for development of biliary complications post living donor liver transplantation, types (stricture anastomotic or not, leak, biloma, stone, cholangitis etc....).
2. Evaluate outcomes of different biliary complications


Eligibility criteria: Inclusion Criteria:

* Adults more than 18 y with living donor liver transplantation in Al-Rajhy liver hospital , Assiut university,Egypt

Exclusion Criteria:

* pediatric liver transplantation
* cadaveric liver transplantation

Primary outcomes:
measure: Incidence of biliary complications
timeFrame: 1 year after liver transplantation
measure: Type of intervention done to each complication
timeFrame: 1 year after liver transplantation
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Al-Rajhy liver hospital
Study officials:
References:
Clinical trial NCT04947683: Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil
Official title: Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Carcinoma
Non-Small-Cell Lung
Lead sponsor: Latin American Cooperative Oncology Group
Sponsor class: OTHER
First posted: 2021-07-01
Enrollment: 101
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diagnostic patients with NSCLC and ALK rearrangement between January 2015 and December 2020.

Brief summary: Observational, retrospective cohort study that will include patients diagnosed with NSCLC and ALK rearrangement between January 2015 and December 2020.


Eligibility criteria: Inclusion Criteria:

* Patients older than 18 years;
* Newly diagnosed advanced stage IIIB-IV NSCLC (AJCC 8th edition) or locally advance/distant relapse in the period of January 2015 to December 2020.
* NSCLC with pathological confirmation of ALK rearrangement by immunohistochemistry, fluorescent in situ hybridization (FISH) or next generation sequencing (NGS);
* ECOG 0-4;
* Patients with CNS metastases are also considered eligible, regardless of the initial treatment instituted.

Exclusion Criteria:

- Incomplete medical chart in terms of date of diagnosis, ALK test results and outcomes

Primary outcomes:
measure: - Describe the treatment sequencing of ALK positive advanced NSCLC in a real-world setting.
timeFrame: December of 2020
measure: - Describe the timelines from the appearance of symptoms, histopathological diagnosis, application of the molecular test, and start of treatment.
timeFrame: December of 2020
Secondary outcomes:
measure: - Estimate the progression-free survival of first-line treatment, and other subsequent lines;
timeFrame: December of 2020
Other outcomes:
measure: - Estimate the overall survival from diagnosis
timeFrame: December of 2020
measure: - Compare patients' outcomes among baseline characteristics defined subgroups;
timeFrame: December of 2020
measure: - Evaluate health economics parameters in the context.
timeFrame: December of 2020
Locations:
city: Fortaleza
country: Brazil
facility: Centro Regional Integrado de Oncologia (CRIO)
state: Ceará
city: Natal
country: Brazil
facility: Liga Norte Riograndense Contra o Câncer
state: Rio Grande Do Norte
city: Rio De Janeiro
country: Brazil
facility: Instituto D'OR
state: RJ
city: Porto Alegre
country: Brazil
facility: CPO Pucrs
state: RS
city: São Paulo
country: Brazil
facility: A.C Camargo Cancer Center
Study officials:
References:
Clinical trial NCT01376583: Exercise Controls Tumor Cell Growth Through AMPK Activation
Official title: Running From Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Breast Cancer
Keywords: Breast cancer
Exercise
Myokines
AMPK
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2011-06-20
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy Danish females in the age 18-30

Brief summary: The study investigates the explanation for the positive relation found between exercise and breastcancer.


Eligibility criteria: Inclusion Criteria:

* Healthy Females age 18-30
* BMI 18-25
* Regular period

Exclusion Criteria:

* Ingestions of any hormones
* Pregnancy
* Chronic inflammation
* Elite athletes

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Centre of Inflammation and Metabolism
Study officials:
affiliation: Centre of Inflammation and Metabolism
name: Bente K Pedersen, Professor
role: STUDY_DIRECTOR
References: